Warning: The NCBI web site requires JavaScript to function. more...
HER2 gene status in primary breast cancers and matched distant metastases.
Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G, Terracciano L, Feichter G, Bubendorf L.
Breast Cancer Res. 2007;9(3):R31.
Related citations
Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y, Booser DJ, Sneige N.
Cancer. 2005 May 1;103(9):1763-9.
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review.
Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C.
Br J Cancer. 2004 Jun 14;90(12):2344-8. Review.
Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN.
Eur Urol. 2011 Aug;60(2):350-7. Epub 2011 May 25.
Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
Dandachi N, Dietze O, Hauser-Kronberger C.
Anticancer Res. 2004 Jul-Aug;24(4):2401-6.
Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.
Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, Larsimont D.
Breast Cancer Res Treat. 2003 Feb;77(3):199-204.
Amplification of the BP1 homeobox gene in breast cancer.
Cavalli LR, Man YG, Schwartz AM, Rone JD, Zhang Y, Urban CA, Lima RS, Haddad BR, Berg PE.
Cancer Genet Cytogenet. 2008 Nov;187(1):19-24.
A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
Aoyama K, Kamio T, Nishikawa T, Kameoka S.
Jpn J Clin Oncol. 2010 Jul;40(7):613-9. Epub 2010 Mar 4.
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.
Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D.
Ann Oncol. 2002 Jul;13(7):1036-43.
Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.
Oncol Rep. 2008 Mar;19(3):651-6.
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
Vincent-Salomon A, Pierga JY, Couturier J, d'Enghien CD, Nos C, Sigal-Zafrani B, Lae M, Fréneaux P, Diéras V, Thiéry JP, Sastre-Garau X.
Br J Cancer. 2007 Feb 26;96(4):654-9. Epub 2007 Jan 30.
HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell'orto P, Veronesi P, Luini A, D'Alessandro C, Cardillo A, Goldhirsch A, Colleoni M.
Eur J Cancer. 2007 Nov;43(16):2339-44. Epub 2007 Sep 12.
HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy.
Santinelli A, Pisa E, Stramazzotti D, Fabris G.
Int J Cancer. 2008 Mar 1;122(5):999-1004.
HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays.
Yau TK, Sze H, Soong IS, Hioe F, Khoo US, Lee AW.
Hong Kong Med J. 2008 Apr;14(2):130-5.
Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.
Sekido Y, Umemura S, Takekoshi S, Suzuki Y, Tokuda Y, Tajima T, Osamura RY.
Int J Oncol. 2003 Jun;22(6):1225-32.
Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis.
Santiago MP, Vázquez-Boquete A, Fernández B, Masa C, Antúnez JR, Fraga M, Forteza J, García-Caballero T.
Histol Histopathol. 2009 Jun;24(6):675-82.
Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
Hanna W, Nofech-Mozes S, Kahn HJ.
Breast J. 2007 Mar-Apr;13(2):122-9.
Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, Paridaens R, De Wolf-Peeters C.
J Clin Oncol. 2008 Oct 20;26(30):4869-74. Epub 2008 Sep 15.
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen RL, Mass RD, Sanders C, Press MF.
Breast Cancer Res Treat. 2005 Sep;93(1):3-11.
Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
Breast. 2008 Oct;17(5):506-11. Epub 2008 May 5.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on